Patient-Reported Outcomes for Scalp, Eyebrow, and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from Two Phase 3 Clinical Trials

Patients with severe alopecia areata (AA) treated with baricitinib for up to 152 weeks reported sustained improvements in scalp, eyebrow (EB), and eyelash (EL) hair regrowth. In the BRAVE-AA1/BRAVE-AA2 trials, adult patients with a Severity of Alopecia Tool (SALT) score ≥50 were randomized to receive either 2mg or 4mg of baricitinib daily. Meaningful improvement was defined as a score of 0/1 with a ≥2-point improvement from baseline. At weeks 52, 104, and 152, 72%, 75%, and 78% of 2mg-treated patients and 86%, 86%, and 82% of 4mg-treated patients reported meaningful scalp hair improvement. EB improvement was seen in 54%, 63%, and 61% of 2mg-treated patients and 64%, 75%, and 75% of 4mg-treated patients. EL improvement was reported in 52%, 69%, and 66% of 2mg-treated patients and 56%, 74%, and 71% of 4mg-treated patients. These results indicate that the benefits of baricitinib for hair regrowth are maintained over a long-term period.